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Influence of various hemodialysis membranes on the plasma (HD) treatment have also been immunocompromised.
(1→3)--D-glucan level. These patients frequently experience opportunistic in-
Background. Recently, invasive fungal infections have in- fections and an especially increased incidence of systemiccreased significantly because of the growing number of immu-
mycosis. A definite diagnosis of systemic mycosis needsnocompromised hosts. The measurement of plasma (1→3)--
D-glucan has been proposed as a useful diagnostic tool for pathological or microbiological evidence of fungal infec-
deep mycosis. In this study, we analyzed the alteration of the tion by biopsy. However, specimens for such examina-
plasma (1→3)--D-glucan concentration by using different kinds tions are difficult to obtain because of the low numberof hemodialysis (HD) membranes in end-stage renal disease
of platelets or the declined status in these patients.(ESRD) patients and estimated its half-life.
Methods. Twenty-seven patients with ESRD without known Therefore, serological or molecular biological methods
fungal infections (with a median age of 66 years old) were en- to detect fungal infection have been investigated as an
rolled in this study. Cellulose triacetate (CTA) membrane, cel- adjunct. (1→3)--D-Glucan is one of the major structurallulose (Cu) membrane, and polymethyl methacrylate (PMMA)
components of fungi and exists only in fungus [3]. Itmembrane were used in three consecutive initiations of HD and
reacts directly to factor G in the Limulus coagulationplasma (1→3)--D-glucan concentration was measured before
and after each HD session. cascade, while endotoxin reacts to factor C [1, 3]. There-
Results. The level did not change between before and after fore, measuring plasma (1→3)--D-glucan is expected
HD when CTA and PMMA membranes were used. In contrast,
to be a noninvasive, quick, and direct diagnostic tool.the plasma (1→3)--D-glucan level increased greatly after HD
Although the sensitivity and specificity for deep mycosisusing the Cu membrane (from 9.4 to 332 pg/mL in median).
Hypothesizing that the plasma (1→3)--D-glucan level declines were reported to be 90 and 100%, respectively [1], false
exponentially, its median half-life is estimated at 20 hours, which positive results could be caused by various factors [4–6].
is not affected by hepatic or renal function.
Some of the HD membranes have been known to in-Conclusions. Because the plasma (1→3)--D-glucan level
crease the plasma (1→3)--D-glucan level [1]. However,increases dramatically after HD using the Cu membrane, dia-
lyzers with Cu membrane should be avoided for HD in patients our extensive literature search found very few reports
with suspected deep mycosis. The measurement of plasma that could show the influence of various HD membranes
(1→3)--D-glucan is also useful for the patients with hepatic
on plasma (1→3)--D-glucan levels with appropriateor renal failure.
controls. Our current study analyzed the effects of differ-
ent HD membranes on the plasma concentration of
(1→3)--D-glucan in patients without known fungal in-Chemotherapy for malignancies and immunosuppres-
fection on the initiation of HD. In addition, we evaluatedsive therapy for autoimmune diseases have become more
the influence of hepatic or renal function on the elimina-intensive in recent years, resulting in the increased num-
tion of plasma (1→3)--D-glucan.ber of immunocompromised patients [1, 2]. Some patients
with end-stage renal disease (ESRD) under hemodialysis
METHODS
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Patients and HDfungal infection.
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Table 1. Characteristics and diagnosis in patients by adding 500 L of 0.04% (wt/vol) sodium nitrite in
0.48 mol/L of HCl. Color development was carried outSex male:female 17:10
Age years (range) 66 (36–90) by adding 500 L each of 0.3% (wt/vol) ammonium
Diagnosis sulfamate and 0.07% (wt/vol) N-1-naphthylethylenedia-Chronic glomerulonephritis 8
mine dihydrochloride. Absorbance of samples and knownDiabetic nephropathy 12
Nephrosclerosis 6 concentrations of controls were measured at 545 nm.
Lupus nephritis 1 Values lower than 20 pg/mL were considered negativeBUN mg/dL 86.1217.10
[1]. This test does not react to endotoxin [1, 3].Cr mg/dL 8.021.76
CCr mL/min 5.613.54
UProtein g/day 2.281.42
Urine volume mL/day 1197522
Albumin g/dL 3.330.59 RESULTS
Total bilirubin mg/dL 0.410.24
Plasma (1→3)--D-glucan level was influenced by CuProthrombin time % 9017
membrane, but not by CTA or PMMA membranesData are N or mean  SD. Abbreviations are: BUN, blood urea nitrogen;
Cr, creatinine; CCr, creatinine clearance; UProtein, urinary protein. Plasma (1→3)--D-glucan levels measured before and
after HD using CTA membrane are shown in Figure 1A.
They were same between before (median 7.9 pg/mL,
range 1 to 27.2 pg/mL) and after (median 9 pg/mL, range
1 to 29.5 pg/mL) HD. In contrast, the plasma (1→3)--patients were shown in Table 1. There were 17 males
and 10 females with a median age of 66 years (range 36 D-glucan level obviously increased from 9.4 pg/mL (range
1.2 to 39.1 pg/mL) to 332 pg/mL (range 108.2 to 2200to 90). The underlying diseases were chronic glomerulo-
nephritis (N 8), diabetic nephropathy (12), nephroscle- pg/mL) in median after HD using Cu membrane (Fig.
1B). The median interval between the second and therosis (6), and lupus nephritis (1). The serum levels of
blood urea nitrogen and creatinine were 86.12  17.10 third HD was 45 hours (range 14 to 93 hours). The
median plasma (1→3)--D-glucan level before the thirdand 8.02 1.76 mg/dL, respectively. The creatinine clear-
ance was 5.6  13.54 mL/min. The serum concentrations HD decreased to 43 pg/mL (range 4.3 to 413.9 pg/mL).
Although its level was various before the third HD, theof albumin and total bilirubin were almost within a nor-
mal range, although two patients had been diagnosed plasma (1→3)--D-glucan concentration did not change
significantly after HD using PMMA membrane (Fig. 1C).with liver cirrhosis. Three different kinds of HD mem-
branes—cellulose triacetate (CTA) membrane, cellulose We measured the (1→3)--D-glucan concentration of
all anticoagulant solutions, dialysate, and filling liquids(Cu) membrane, and polymethyl methacrylate (PMMA)
membrane—were used in three consecutive HD ses- in wet type dialyzers used in this study. The (1→3)--D-
glucan concentration of the filling liquid in Cu membranesions. The plasma (1→3)--D-glucan level was measured
at the beginning (before) and the end (after) of each was 305,200 pg/mL, whereas the levels were below
1.0 pg/mL in all other solutions. These data supportedHD session. Arteriovenous fistula was used as a blood
access for each HD. HD was continued for three hours that only Cu membrane was responsible for the increase
in plasma (1→3)--D-glucan concentration.in each procedure. The blood flow was 120 mL/min when
using the CTA membrane and 150 mL/min when using
the Cu or PMMA membrane. Although different antico-
Half-life of plasma (1→3)--D-glucanagulants, such as heparin sodium, dalteparin sodium, or
nafamostat mesilate, were used, the anticoagulant was To evaluate the influence of renal or hepatic function
not changed in the three consecutive HD in each patient. on the elimination of plasma (1→3)--D-glucan, we esti-
mated the plasma half-life of (1→3)--D-glucan by hypoth-
esizing that the (1→3)--D-glucan level declines exponen-
Plasma (1→3)--D-glucan assay tially. The median half-life of plasma (1→3)--D-glucan
Plasma levels of (1→3)--D-glucan were measured was 20 hours (range 3.1 to 181.3 hours; Table 2). The
using the Fungi-Tec G test (Seikagaku Kogyo Corpora- relationships between the plasma half-life of (1→3)--
tion, Tokyo, Japan) [1, 7] according to manufacturer’s D-glucan and serum creatinine concentration, creatinine
instructions. Plasma samples (100 L) were treated with clearance, daily amount of proteinuria, daily urine vol-
200 L of 0.32 mol/L perchloric acid (PCA) at 37C ume, prothrombin activity, or serum albumin concentra-
for 20 minutes to precipitate plasma components that tion were analyzed. As shown in Figure 2, no relationship
interfere with the test. The supernatant (100 L) was was observed between the plasma half-life of (1→3)--
then added to 100 L of G test reagent dissolved in 0.2 D-glucan and those factors. These findings suggest that
mol/L Tris-HCl buffer (pH 8.0). The mixture was incu- hepatic and renal function have no effect on the half-
life of plasma (1→3)--D-glucan.bated at 37C for 30 minutes. The reaction was stopped
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Fig. 1. Relationship between plasma (1→3)--D-glucan concentration and hemodialysis (HD) membranes. (A) The plasma (1→3)--D-glucan
concentration before and after HD with a cellulose triacetate (CTA) membrane. Its level did not alter between before and after HD. (B) The
plasma (1→3)--D-glucan concentration before and after HD with a cellulose (Cu) membrane. Its level was extremely high after HD with Cu
membrane. (C) The plasma (1→3)--D-glucan concentration before and after HD with a polymethyl methacrylate (PMMA) membrane. Its level
did not alter between before and after HD. Y-axis is a logarithmic scale of plasma (1→3)--D-glucan concentration.
Table 2. Half-life of plasma (1→3)--D-glucan
-D-glucan -D-glucan before Interval between Calculated half-life of
after Cu-HD PMMA-HD two HD -D-glucan
No. pg/mL hours
1 1208 9.6 93 23.93
2 296.8 18.8 45 11.30
3 1727 8.7 69 9.21
4 111.1 14.7 45 12.25
5 332 10.2 45 10.01
6 163.5 52.3 93 23.23
7 901 168.5 69 16.80
8 2200 55.4 69 18.62
9 285.6 101.4 45 19.02
10 393.6 413.9 45 23.00
11 491.6 21.3 45 181.30
12 311.6 47.1 93 24.03
13 461.5 297.8 93 28.25
14 1729 55.1 45 17.73
15 319.2 29 69 27.23
16 500.5 32.8 93 22.63
17 332.6 43 93 27.83
18 236.1 81.7 45 18.32
19 245.1 71.7 45 25.38
20 108.3 4.8 45 10.01
21 1102 43.7 93 19.97
22 294.1 66 45 20.87
23 456.4 35.2 93 25.16
24 188.9 8.4 14 3.12
25 266.8 157.6 45 59.25
26 382.5 36 45 13.20
27 309.6 25.8 45 12.55
MeanSD 546.8548.62 70.7693.20 61.6323.39 26.0832.65
Median (range) 332 (108.3–2200) 43 (4.8–413.9) 45 (14–93) 19.97 (3.12–181.3)
Abbreviations are: Cu-HD, hemodialysis with a cellulose; PMMA-HD, hemodialysis with polymethyl methacrylate; HD, hemodialysis.
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Fig. 2. Relationship between the half-life of plasma (1→3)--D-glucan and various parameters of hepatic or renal function. The Y-axis is the
estimated half-life of plasma (1→3)--D-glucan, and the X-axis is indicated in each graph. The half-life of plasma (1→3)--D-glucan was not
related to various factors of hepatic or renal function.
DISCUSSION conditions, including blood access, blood flow, or HD
duration, were arranged identically. These interventionsThe determination of the plasma (1→3)--D-glucan
made it possible to evaluate the unbiased effect of eachlevel is a highly sensitive and specific test for invasive
membrane on the plasma (1→3)--D-glucan level. Indeep mycosis. Obayashi et al reported that its sensitivity
addition, to our knowledge there have been no humanand specificity for deep mycosis were 90 and 100%, re-
data collected on the elimination of (1→3)--D-glucanspectively [1]. However, subsequent studies showed that
from plasma. Therefore, we estimated the plasma half-the sensitivity and specificity were 27 to 86.5% and 75
life of (1→3)--D-glucan. This is important because with-to 93.8%, respectively [1, 7–9]. In spite of the good speci-
out knowing its half-life, it may be difficult to determineficity results in these reports, in the clinical situation
whether a patient still has an active fungal infection whenthere has been a potential interference in this system.
the plasma (1→3)--D-glucan level is persistently high,False-positive reactions have been reported in patients
especially with hepatic or renal dysfunction.receiving human immunoglobulin products, which con-
We showed the results demonstrating that the plasmatain factor G-reactive materials [3, 10], drugs containing
(1→3)--D-glucan level was not affected by HD using(1→3)--D-glucan, for example, lentinan, crestin, sceer-
CTA or PMMA membranes but was extremely increasedoglucan, schizophyllan, and sulfa drugs [5], and gaze
after HD using a Cu membrane. It was suggested thatglucan for surgeries [4]. In addition, Limulus amebocyte
the main mechanism of these observation was the con-lysate (LAL)-reactive material from the cupro-ammo-
tamination of the (1→3)--D-glucan in Cu membranenium rayon membrane used in HD was considered to
into blood during HD because the (1→3)--D-glucan ofcause false-positive results [11]. However, previous anec-
the filling liquid in Cu membrane showed an extremelydotal studies on the effect of HD were not performed
high level. Therefore, the plasma (1→3)--D-glucan mea-in a well-designed manner. We prospectively enrolled
only patients at the initiation of HD, so that the HD surements could be used as an aid to diagnose fungal
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